Thursday, 29 March 2018

Accepted Abstracts

PULSUS Group Welcomes all the participants across the world to attend ‘World Congress on Diabetes and Endocrinology’ to be control throughout August 22-23, 2018 Rome, Italy which has prompt keynote displays, Oral talks, Poster displays and Exhibitions. WDEC 2018 strives to bring renowned scientists, Physicians, Surgeons, Professors, Instrumentalists, Medical and Industrial professions, young researchers, students and Business delegates under a single roof providing an opportunity to share the knowledge and scientific progress in the field of  Diabetes and Endocrinology shaping the future research.

The following are the speakers, Accepted Abstracts.


Name Lue Ping Zhao  
Affiliation: University of Washington, USA
Title: Building and Validating a Prediction model for Pediatric Type 1 Diabetes Risk Using Next Generation Targeted Sequencing of Class II HLA Genes

Aim: It is of interest to predict possible lifetime risk of type diabetes (T1D) in young children for recruiting high-risk subjects into longitudinal studies of effective prevention strategies.
Methods: Utilizing a case-control study in Sweden, we applied a recently developed next generation targeted sequencing (NGTS) technology to genotype  class II genes, and applied an object-oriented regression (OOR) to build and validate a prediction model for T1D.
Results: In the training set, estimated risk scores were significantly different between patients and controls (P=8.12*10-92), and the area under the curve (AUC) from the receiver operating characteristic (ROC) analysis was 0.917. Using the validation data set, and more 


Name: Chandran Saha

Affiliation: Director of Biostatistics Core, DTRC Indiana University School of Medicine, USA

Title: Program ACTIVE II: Outcomes from a Multi-State Community-Based Depression Treatment for Rural and Urban Adults with Type 2 Diabetes & The two year outcomes and cost effectiveness of a commercial weight loss program for the prevention of type 2 diabetes: a randomized control trial

In spite of solid evidence that risk for developing type 2 diabetes can be prevented by lifestyle interventions, it has been difficult to scale prevention research to address the growing public health demand. This study, conducted in Indianapolis, Indiana in 2013-16, investigated if a widely available weight management program (Weight Watchers- WW) could cost effectively achieve and sustain sufficient weight loss in persons and more 


Name: Ahdy W. Helmy

Affiliation:  Indiana University, USA

Title: Program ACTIVE II: Outcomes from a Multi-State Community-Based Depression Treatment for Rural and Urban Adults with Type 2 Diabetes & The two year outcomes and cost effectiveness of a commercial weight loss program for the prevention of type 2 diabetes: a randomized control trial

Non-alcoholic fatty liver disease (NAFLD) as a broad category, it encompasses simple steatosis to that with hepatitis, fibrosis, cirrhosis, and even hepatocellular carcinoma. NAFLD is a growing health crisis, in the US, and the West, the prevalence is 20-40%. In part, due to visceral obesity, insulin resistance, metabolic syndrome, excess lipolysis, and atherogenic dyslipidemia.
The flying fatty acids like loose cannons, and more  



Contact Person : John Kyle, endocrinology@cmesocietyconferences.com
Reach us @ Facebook, Twitter, LinkedIn, Word Press